Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12

References

• Labarthe MC, Halanek N, Birchall L, Russell N, Desel C, Todryk S, Peters MJ, Lucas A, Falkenberg FW, Dalgleish AG, et al. The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model. Cancer Immunol Immunother 2006; 55:277-88; PMID:16158275; http://dx.doi.org/10.1007/s00262-005-0061-2
   PubMed Web of Science ®Google Scholar
• Srivatsan S, Patel JM, Bozeman EN, Imasuen IE, He S, Daniels D, Selvaraj P. Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccin Immunother 2014; 10:52-63; PMID:24064957; http://dx.doi.org/10.4161/hv.26568
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384:1109-17; PMID:25034862; http://dx.doi.org/10.1016/S0140-6736(14)60958-2
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30; PMID:24590637; http://dx.doi.org/10.1200/JCO.2013.53.0105
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Nanda R, Chow L, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Dolled-Filhart M, Emancipator K, Gonzalez EJ, et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia, PA: AACR; Cancer Res 2015;75(9 Suppl):Abstract nr S1-09.
   Google Scholar
• Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D, Bertucci F. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget 2014; 2015 Mar 10;6(7):5449-64
   Google Scholar
• Wei WZ, Shi WP, Galy A, Lichlyter D, Hernandez S, Groner B, Heilbrun L, Jones RF. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 1999; 81:748-54; PMID:10328228; http://dx.doi.org/10.1002/(SICI)1097-0215(19990531)81:5%3c748::AID-IJC14%3e3.0.CO;2-6
   PubMed Web of Science ®Google Scholar
• Bozeman EN, Cimino-Mathews A, Machiah DK, Patel JM, Krishnamoorthy A, Tien L, Shashidharamurthy R, Selvaraj P. Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model. Vaccine 2013; 31:2449-56; PMID:23541884; http://dx.doi.org/10.1016/j.vaccine.2013.03.028
   PubMed Web of Science ®Google Scholar
• Veenstra JJ, Gibson HM, Littrup PJ, Reyes JD, Cher ML, Takashima A, Wei WZ. Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity. Cancer Res 2014; 74:5409-20; PMID:25092895; http://dx.doi.org/10.1158/0008-5472.CAN-14-0501
   PubMed Web of Science ®Google Scholar
• Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3:269-80; PMID:16683005; http://dx.doi.org/10.1038/ncponc0509
   PubMedGoogle Scholar
• Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997; 90:2541-8; PMID:9326219
   PubMed Web of Science ®Google Scholar
• Kusumoto M, Umeda S, Ikubo A, Aoki Y, Tawfik O, Oben R, Williamson S, Jewell W, Suzuki T. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother 2001; 50:373-81; PMID:11676397; http://dx.doi.org/10.1007/s002620100213
   PubMed Web of Science ®Google Scholar
• Choi KJ, Kim JH, Lee YS, Kim J, Suh BS, Kim H, Cho S, Sohn JH, Kim GE, Yun CO. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther 2006; 13:1010-20; PMID:16525479; http://dx.doi.org/10.1038/sj.gt.3302759
   PubMed Web of Science ®Google Scholar
• Coughlin CM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G, Eck SL. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res 1995; 55:4980-7; PMID:7585539
   PubMed Web of Science ®Google Scholar
• McHugh RS, Nagarajan S, Wang YC, Sell KW, Selvaraj P. Protein transfer of glycosyl-phosphatidylinositol-B7-1 into tumor cell membranes: a novel approach to tumor immunotherapy. Cancer Res 1999; 59:2433-7; PMID:10344754
   PubMed Web of Science ®Google Scholar
• Cayeux S, Beck C, Aicher A, Dorken B, Blankenstein T. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur J Immunol 1995; 25:2325-31; PMID:7545119; http://dx.doi.org/10.1002/eji.1830250831
   PubMed Web of Science ®Google Scholar
• Cayeux S, Beck C, Dorken B, Blankenstein T. Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant. Hum Gene Ther 1996; 7:525-9; PMID:8800747; http://dx.doi.org/10.1089/hum.1996.7.4-525
   PubMed Web of Science ®Google Scholar
• Muenst S, Schaerli AR, Gao F, Daster S, Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2014; 146:15-24; PMID:24842267; http://dx.doi.org/10.1007/s10549-014-2988-5
   PubMed Web of Science ®Google Scholar
• Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2013; 139:667-76; PMID:23756627; http://dx.doi.org/10.1007/s10549-013-2581-3
   PubMed Web of Science ®Google Scholar
• Pilon-Thomas S, Mackay A, Vohra N, Mule JJ. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol 2010; 184:3442-9; http://dx.doi.org/10.4049/jimmunol.0904114
   PubMed Web of Science ®Google Scholar
• Ha SJ, Mueller SN, Wherry EJ, Barber DL, Aubert RD, Sharpe AH, Freeman GJ, Ahmed R. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med 2008; 205:543-55; PMID:18332181; http://dx.doi.org/10.1084/jem.20071949
   PubMed Web of Science ®Google Scholar
• Li F, Zhao C, Wang L. Molecular-targeted agents combination therapy for cancer: developments and potentials. Int J Cancer 2014; 134:1257-69; PMID:23649791; http://dx.doi.org/10.1002/ijc.28261
   PubMed Web of Science ®Google Scholar
• Luu T, Chung C, Somlo G. Combining emerging agents in advanced breast cancer. Oncologist 2011; 16:760-71; PMID:21543509; http://dx.doi.org/10.1634/theoncologist.2010-0345
   PubMed Web of Science ®Google Scholar
• Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 2014; 11:509-24; PMID:25001465; http://dx.doi.org/10.1038/nrclinonc.2014.111
   PubMed Web of Science ®Google Scholar
• Hanna MG, Jr., Hoover HC, Jr., Vermorken JB, Harris JE, Pinedo HM. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 2001; 19:2576-82; PMID:11257395; http://dx.doi.org/10.1016/S0264-410X(00)00485-0
   PubMed Web of Science ®Google Scholar
• Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999; 59:5160-8; PMID:10537292
   PubMed Web of Science ®Google Scholar
• Rao JB, Chamberlain RS, Bronte V, Carroll MW, Irvine KR, Moss B, Rosenberg SA, Restifo NP. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol 1996; 156:3357-65
   PubMed Web of Science ®Google Scholar
• Armstrong CA, Botella R, Galloway TH, Murray N, Kramp JM, Song IS, Ansel JC. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res 1996; 56:2191-8; PMID:8616871
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol 2015; 33:1974-82; PMID:25605845; http://dx.doi.org/10.1200/JCO.2014.59.4358
   PubMed Web of Science ®Google Scholar
• Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005; 65:1089-96; PMID:15705911
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515:568-71; PMID:25428505; http://dx.doi.org/10.1038/nature13954
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Fu J, Malm IJ, Kadayakkara DK, Levitsky H, Pardoll D, Kim YJ. Preclinical evidence that PD-1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res 2014; 74(15):4042-52
   PubMed Web of Science ®Google Scholar
• Li B, VanRoey M, Wang C, Chen TH, Korman A, Jooss K. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor–secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res 2009; 15:1623-34; PMID:19208793; http://dx.doi.org/10.1158/1078-0432.CCR-08-1825
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 2003; 170:6338-47; http://dx.doi.org/10.4049/jimmunol.170.12.6338
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90:3539-43
   PubMed Web of Science ®Google Scholar
• Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21:3343-50; PMID:12947071; http://dx.doi.org/10.1200/JCO.2003.07.005
   PubMed Web of Science ®Google Scholar
• Eager R, Nemunaitis J. GM-CSF gene-transduced tumor vaccines. Mol Ther 2005; 12:18-27; PMID:15963916; http://dx.doi.org/10.1016/j.ymthe.2005.02.012
   PubMed Web of Science ®Google Scholar
• Pizzoferrato E, Chu NR, Hawley TS, Lieu FH, Barber BH, Hawley RG, Watts TH, Berinstein NL. Enhanced immunogenicity of B cell lymphoma genetically engineered to express both B7-1 and interleukin-12. Hum Gene Ther 1997; 8:2217-28; PMID:9449375; http://dx.doi.org/10.1089/hum.1997.8.18-2217
   PubMed Web of Science ®Google Scholar
• Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K, Nakamura H, Furukawa K, Kanematsu T, Shiku H. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997; 159:1336-43
   PubMed Web of Science ®Google Scholar
• Ikuta Y, Okugawa T, Furugen R, Nagata Y, Takahashi Y, Wang L, Ikeda H, Watanabe M, Imai S, Shiku H. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes. Int J Cancer 2000; 87:553-8; PMID:10918197; http://dx.doi.org/10.1002/1097-0215(20000815)87:4%3c553::AID-IJC15%3e3.0.CO;2-8
   PubMed Web of Science ®Google Scholar
• Landuzzi L, Antognoli A, Nicoletti G, Croci S, Palladini A, Ianzano ML, Murgo A, Stivani V, Grosso V, Nanni P, et al. HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines. Vaccine 2011; 29:4690-7; PMID:21569812; http://dx.doi.org/10.1016/j.vaccine.2011.04.096
   PubMed Web of Science ®Google Scholar
• Nanni P, Landuzzi L, Nicoletti G, De Giovanni C, Rossi I, Croci S, Astolfi A, Iezzi M, Di Carlo E, Musiani P, et al. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J Immunol 2004; 173:2288-96; http://dx.doi.org/10.4049/jimmunol.173.4.2288
   PubMed Web of Science ®Google Scholar
• De Giovanni C, Nicoletti G, Landuzzi L, Astolfi A, Croci S, Comes A, Ferrini S, Meazza R, Iezzi M, Di Carlo E, et al. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res 2004; 64:4001-9; PMID:15173014; http://dx.doi.org/10.1158/0008-5472.CAN-03-2984
   PubMed Web of Science ®Google Scholar